Genotyping Assay Market Size
The global genotyping assay market reached USD 17.16 billion in 2025 and is expected to reach USD 40.22 billion by 2033, growing at a CAGR of 10.6% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by increasing demand for precision medicine, rising prevalence of genetic disorders, and expanding applications in oncology, pharmacogenomics, and infectious disease research. The growing adoption of personalized healthcare and advancements in genomic technologies are further accelerating market expansion.
Market growth is strongly supported by continuous advancements in high-throughput genotyping technologies, including PCR-based methods, microarrays, and next-generation sequencing. Research institutions and biopharmaceutical companies are increasingly investing in genotyping assays for drug discovery, biomarker identification, and clinical research. At the same time, rising integration of automation and artificial intelligence in genomic analysis is enhancing efficiency and accuracy, while supportive regulatory frameworks are facilitating broader adoption.
Genotyping assays play a critical role in identifying genetic variations, enabling disease risk assessment, and guiding targeted therapeutic decisions. Advancements in multiplexing, miniaturisation, and data analytics are improving scalability and cost-effectiveness. Furthermore, expanding applications in agriculture, ancestry testing, and population genomics are broadening the scope of genotyping technologies. With strong momentum in genomics research, precision medicine, and technological innovation, the genotyping assay market is poised for sustained and transformative growth.
Genotyping Assay Market Dynamics
The factors influencing the genotyping assay market are the growing importance of genotyping assays and the technological advancements that are expected to drive the market growth.
The growing importance of genotyping assays is expected to drive the market growth in the forecast period
Researchers can use genotyping to investigate genetic variants such as single-nucleotide polymorphisms (SNPs) and large structural changes in DNA. High-throughput genomic technologies like next-generation sequencing (NGS) and microarrays allow for a more in-depth understanding of disease aetiology at the molecular level.
With multiple genomic targets potentially contributing to disease, an analysis must be flexible and precise. Data analysis tools for SNP genotyping and copy number variation (CNV) can analyze results for millions of markers and probes and detect sample outliers, providing insight into the functional consequences of genetic variation. Genotyping can help us understand disease mechanisms, predict an individual's risk of developing certain diseases, and even aid in developing personalized therapies. Biosystems for Applied Research TaqMan SNP genotyping assays have been used to identify variants linked to blood disorders and a variety of other diseases. TaqMan SNP genotyping assays require a double-stranded DNA template, the Taq polymerase enzyme, and two forward and reverse primers specific to the amplified sequence. Unlike gene expression qPCR, SNP detection necessitates using two probes with different fluorescent reporters. This allows homozygous and heterozygous samples to be distinguished.
Limitations associated with genotyping assay is expected to hamper the market growth
WGR genotyping has traditionally been carried out using paired-end Illumina technology, which, according to a survey, costs approximately $400 per sample for a genome of 1 Gb and 10 average sequencing depth. WGR-based GWAS, which typically involves a few hundred individuals, may cost several hundred dollars for crops with large genomes. Reduced average sequencing depth can reduce WGR costs; however, this may result in an unacceptable number of genotyping errors.
Furthermore, although genotyping errors affect most data and can significantly impact a study's biological conclusions, they are too often overlooked. Genotyping errors can arise from various complex and sometimes cryptic causes, including the primary DNA sequence, low quality or quantity of the DNA sample, biochemical artifacts, or human factors.
Genotyping Assay Market Segment Analysis
By technology, the PCR segment is expected to dominate the market in the forecast period
PCR genotyping employs the widely used polymerase chain reaction technique for genetic analysis. DNA or RNA sequences are amplified with specific primers and electrophoretically analyzed for size and quality before being extracted and purified. Genotyping enables researchers to investigate large structural variations and small genetic changes in DNA, such as single nucleotide polymorphisms (SNPs). Real-time PCR is a high throughput genotyping method that uses molecular probes to produce quick and accurate results. Real-time PCR is a high throughput genotyping method that uses molecular probes to produce quick and accurate results. Our qPCRBIO Probe Mixes are compatible with all dual-labeled allele-specific probes and can be used for reliable allelic discrimination. Another real-time genotyping system is High-Resolution Melt, a post-PCR application (HRM).
Many companies are launching PCR genotyping assay products and are expected to drive market growth. For instance, on 2nd February 2021, Novacyt S.A launched PCR genotyping assay portfolio under the brand name SNPsig, to diagnose new variants of SARS-CoV-2.
Genotyping Assay Market Scope
Metrics | Details |
| Market CAGR | 10.6% |
| Segments Covered | By Product, By Technology, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Genotyping Assay Market Geographical Analysis
North America region is expected to hold the largest market share in the global genotyping assay market
The greater technological and government support and the presence of major players in the region are expected to drive the market growth. Furthermore, increased R&D funding is expected to fuel market growth over the forecast period. Thermo Fisher Scientific is based in the United States that manufactures and distributes scientific instruments, reagents and consumables, and software services. TaqMan SNP Genotyping Assay uses TaqMan 5'nuclease chemistry to amplify and detect specific polymorphisms in purified genomic DNA samples. Each assay uses two sequence-specific primers, and two TaqMan minor groove binder (MGB) probes with non-fluorescent quenchers to genotype individuals for a single nucleotide polymorphism (SNP) (NFQ).
Recent Developments
February 2026: Increasing adoption of precision medicine and rising demand for genetic testing significantly accelerated growth of genetic testing, driving widespread use of genotyping assays in clinical diagnostics and research.
January 2026: Advancements in next-generation sequencing and PCR technologies enhanced sequencing technology, enabling high-throughput, accurate, and cost-effective genotyping across large sample volumes.
December 2025: Leading companies such as Thermo Fisher Scientific, Illumina, F. Hoffmann-La Roche, QIAGEN, and Bio-Rad Laboratories expanded investments in product innovation, focusing on advanced assay kits, automated platforms, and integrated bioinformatics solutions.
November 2025: Increasing application of genotyping in pharmacogenomics and personalized therapies drove demand for precision diagnostics, improving drug response prediction and treatment outcomes.
October 2025: Growing adoption of high-throughput platforms and automation in laboratories improved workflow efficiency, reducing turnaround time and operational costs in genotyping processes.
September 2025: Expanding use of genotyping assays in agriculture, biotechnology, and disease research strengthened application expansion, supporting crop improvement, genetic studies, and epidemiological research.
The market is rapidly evolving toward high-throughput, technology-driven genomic solutions, where advancements in sequencing, automation, and bioinformatics are enhancing accuracy, scalability, and clinical adoption of genotyping assays across healthcare and research applications.
Genotyping Assay Market Competitive Landscape
The global genotyping assay market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, LGC, Biosearch Technologies, Roche Diagnostics, Fluidigm Corporation, PerkinElmer, Bio-Rad Laboratories, Integrated DNA Technologies.
Illumina
Overview: Illumina, Inc. is a company based in the United States. Illumina was founded on April 1, 1998. The company develops, manufactures, and sells integrated systems for analyzing genetic variation and biological function.
Product Portfolio: The iSeq 100 System is well-suited for small whole-genome sequencing (for example, bacteria, viruses, and plasmids), targeted sequencing of a subset of genes or gene regions, gene expression analysis, and 16S metagenomics.
Key Development: On January 8th, 2018, The iSeqTM 100 Sequencing System was launched by Illumina, Inc. The new next-generation sequencing (NGS) system provides exceptional data accuracy at a low capital cost, allowing Illumina technology accessible to virtually any lab.
